Demands For Extreme Diligence Will Be Balanced By Need For Deals
Executive Summary
A swing to excessive due diligence reviews by pharmaceutical companies will continue to be balanced by the urgency of acquiring late-stage products, Pharmacia VP-Licensing Thomas Picone, PhD, told a biotech meeting in late February
You may also be interested in...
Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions
Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies
Bristol/ImClone Erbitux BLA Timeline Depends On Merck KGaA Phase II Study
ImClone's timeline for refiling its Erbitux BLA hinges on completion of Merck KGaA's Phase II study in colorectal cancer patients
House Erbitux Probe Widens To Firms That Considered ImClone Partnership
The House Energy & Commerce Committee is widening its Erbitux investigation to include several companies who considered partnering with ImClone on the colorectal cancer drug